Timothy Lesaca: How SSRIs Influence Hemostasis Through Platelets
Timothy Lesaca, Child And Adolescent Psychiatrist at Transformations Care Network, shared a post on LinkedIn:
“SSRIs and Bleeding Risk
Selective serotonin reuptake inhibitors’ association with increased bleeding risk reflects an important pharmacological principle: drugs targeting neurotransmitter systems often exert clinically significant effects outside the central nervous system.
This effect is mediated through platelets.
Unlike neurons, platelets lack the ability to synthesize serotonin.
Instead, they depend on uptake from plasma via the serotonin transporter (SERT), the same target inhibited by SSRIs.
Under normal conditions, serotonin is stored in platelet dense granules and released during activation, where it amplifies aggregation and promotes vasoconstriction at sites of vascular injury.
This contributes to primary hemostasis.
SSRIs inhibit SERT on platelets, preventing serotonin uptake.
Over time, this leads to depletion of intraplatelet serotonin stores.
The result is impaired platelet aggregation, particularly in response to weak agonists, and reduced amplification of the hemostatic response.
Importantly, this does not abolish clotting.
Rather, it reduces the efficiency and stability of platelet plug formation.
Clinically, this manifests as an increased tendency toward mucosal and superficial bleeding.
The most consistently observed association is with upper gastrointestinal bleeding.
Several large observational studies and meta-analyses have demonstrated that SSRI use is associated with approximately a 1.5–2-fold increased risk of GI bleeding.
This risk becomes substantially higher when SSRIs are combined with other agents that affect hemostasis.
Nonsteroidal anti-inflammatory drugs (NSAIDs) impair platelet aggregation via cyclooxygenase-1 inhibition and also disrupt gastric mucosal integrity.
When combined with SSRIs, the risk of GI bleeding increases synergistically, with estimates ranging from 3- to 6-fold compared to baseline.
Anticoagulants and antiplatelet agents further amplify this effect.
Not all SSRIs carry equal risk.
Agents with higher affinity for SERT, such as fluoxetine, sertraline, and paroxetine, are more strongly associated with platelet serotonin depletion and may confer a higher bleeding risk compared to agents with lower SERT affinity.
This suggests a dose- and potency-dependent effect.
From a clinical standpoint, risk stratification is essential.
Higher-risk populations include:
- older adults
- patients with prior gastrointestinal bleeding
- those taking NSAIDs, anticoagulants, or dual antiplatelet therapy
- patients with liver disease or coagulopathy
- High Risk: Fluoxetine, Paroxetine, Sertraline
- Moderate Risk: Citalopram, Escitalopram, Fluvoxamine
- Lower Risk: Bupropion, Mirtazapine
This phenomenon highlights a broader concept in psychopharmacology.
Neurotransmitter systems are not confined to the brain.
Peripheral expression of targets such as SERT means that centrally acting drugs can influence systemic physiology in meaningful ways.”
Stay updated with Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:44Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow